A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)

PURPOSE: We report a phase II clinical study of the combination of irinotecan (CPT-11) and pegylated liposomal doxorubicin (PLD) in platinum- and taxane-resistant recurrent ovarian cancer, based on the recommended doses determined in a phase I trial. METHODS: PLD was administered intravenously at a...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Chemother Pharmacol
Asıl Yazarlar: Shoji, Tadahiro, Takatori, Eriko, Omi, Hideo, Kagabu, Masahiro, Honda, Tatsuya, Futagami, Masayuki, Yokoyama, Yoshihito, Kaiho, Michiko, Tokunaga, Hideki, Otsuki, Takeo, Takano, Tadao, Yaegashi, Nobuo, Kojimahara, Takanobu, Ohta, Tsuyoshi, Nagase, Satoru, Soeda, Shu, Watanebe, Takafumi, Nishiyama, Hiroshi, Sugiyama, Toru
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Berlin Heidelberg 2017
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5532405/
https://ncbi.nlm.nih.gov/pubmed/28656383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3363-0
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller